The digital health solution, dubbed NeuroRPM, is an AI-powered disease management platform that comes with the most advanced and comprehensive monitoring capabilities for Parkinson’s disease on a new wearable device
NeuroRPM is an AI-powered App on Apple Watch. (Credit: Brandon Romanchuk on Unsplash)
NeuroRPM has received the US Food and Drug Administration (FDA) approval for its Apple Watch-based AI-powered remote monitoring solution for Parkinson’s disease.
The digital health solution, dubbed NeuroRPM, is an AI-powered disease management platform, offered as an App on the Apple Watch.
NeuroRPM comes with the most advanced and comprehensive monitoring capabilities for Parkinson’s disease on a new wearable device.
It allows for everyday tracking of the complete range of disease symptoms, said the US-based digital health company.
The University of Maryland functional neurosurgery director Alexander Ksendzovsky said: “The clearance of NeuroRPM is a major milestone in the fight against Parkinson’s disease.
“This technology will allow for unprecedented insights into the symptoms of Parkinson’s disease including bradykinesia, tremor, and dyskinesia, using critical health and wellness data from Apple Watch.
“NeuroRPM is able to assess even slight changes with accuracy comparable to that of a neurologist. This changes the game for the treatment of Parkinson’s patients.”
NeuroRPM said that its AI remote monitoring solution is a result of years of intellectual property development, clinical trials and technical research.
It represents a major step in the management of Parkinson’s disease, and will transform the way Parkinson’s disease is monitored and managed, said the company.
NeuroRPM contains unique algorithms integrated into an Apple Watch app, which collects data passively through the user’s everyday use of the easy-to-use app.
The app will continuously monitor symptoms and health metrics of Parkinson’s disease.
It is currently offered as a prescription-only product and uses data only from Apple Watch, which has been selected by the users to share with the app.
NeuroRPM president Atila Omer said: “We are thrilled to be on the new frontier of digital health with NeuroRPM.
“By leveraging the power of Apple Watch, we are transforming the way individuals with Parkinson’s disease understand their health, enabling care providers to make more informed clinical decisions which will lead to better health outcomes.”